OrbiMed

OrbiMed is a New York-based dedicated healthcare investment firm founded in 1989, managing more than $20 billion in assets across public equities, private equity, venture capital, and royalty financing vehicles, widely regarded as the largest healthcare-dedicated investment manager in the world. The firm invests from seed through public market stages with initial venture checks from $10 million to $100 million in biopharmaceutical, medical technology, diagnostics, and digital health companies. Portfolio companies include Acceleron Pharma, acquired by Bristol-Myers Squibb for $11.4 billion; FLJ Biosciences, a clinical-stage biotechnology company; Karuna Therapeutics, acquired by Bristol-Myers Squibb for $14 billion; and Passage Bio, the gene therapy company that completed a Nasdaq IPO. Beyond its original investments, the portfolio includes hundreds of additional healthcare and biopharmaceutical companies.